BioSpace News Archive

Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.

Wave Life Sciences Ltd. announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share.

Axsome Therapeutics, Inc. is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist.

89bio, Inc. today announced the pricing of its previously announced upsized underwritten public offering of 15,135,135 shares of its common stock at a public offering price per share of $9.25.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of additional translational data from the AWARE-1 breast cancer window-of-opportunity study conducted in combination with SOLTI-Innovative Cancer Research at The San Antonio Breast Cancer Symposium (SABCS).

Tilde Sciences, a specialty pharmaceutical company, announced today that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.

Remix Therapeutics today announced an upcoming presentation introducing REM-422, the Company’s potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers.

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), today announced the closing of an oversubscribed and upsized $90 million Series A financing co-led by Third Rock Ventures and an undisclosed healthcare fund.

Marengo Therapeutics, Inc. today announced a publication in Science Advances describing the novel immunological effects of its foundational anti-Vβ chain TCR targeting antibodies on human T cells.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY ® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY ® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis .